Blog Archives

The Burden Of Diabetes

On: August 14, 2013 By: robsem Posted in Blog, Health

Once you are diagnosed with diabetes, you are a diabetic for life. That’s often said and it is true. Diabetes mellitus is a lifetime illness that involves high blood sugar levels which promotes complications if neglected. But it is not the high blood sugar level that kills you, it’s the complication. Hence, being a diabetic, one needs continuing medical care to achieve target blood sugar levels to prevent these complications. The burden of diabetes is steadily increasing globally. Because of rapid urbanization, change in nutrition brought about by the increasing popularity of fast food due to the busy lifestyle of » » » [Read more]

Diabetic Ketoacidosis In A Patient With Thyroid Storm: A Case Report

On: July 10, 2013 By: Odessa Wilson, MD, FPCP Posted in Blog, Medical Journals

M.K., a 25 year-old female, Filipina-Japanese, presented at the Emergency Room due to abdominal pain. Her aunt stated that she had been noted to be very irritable for the past week before consult but attributed it to stress from the patient’s new job. She had been complaining of epigastric pain but only took AlMgOH, an antacid, which provided slight relief. The patient also claimed that she had been having nausea and had poor appetite, hence did not inject insulin for the past 2 days. She also experienced palpitation, heat intolerance, hyperdefecation and lightheadedness. The patient is a diagnosed case of » » » [Read more]

A Comparative Study of the Effect of Vildagliptin and Glimepiride on Glucose Variability in Type 2 Diabetic Patients With Inadequate Glycemic Control on Metformin

On: July 1, 2013 By: Odessa Wilson, MD, FPCP Posted in Blog, Medical Journals

Authors: Odessa G. Tolentino-Wilson, M.D., FPCP Augusto D. Litonjua, M.D., FPCP, FPSEM, FACE Section of Endocrinology and Metabolism Makati Medical Center INTRODUCTION: Vildagliptin is a member of the dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) class of drugs. These drugs are believed to improve glucose variability by restoring the physiologic pattern of insulin secretion. Vildagliptin improves glycemia by improving beta and alpha cells’ sensitivity to glucose.1 This addresses the impaired glucose-mediated suppression of glucagon secretion in diabetes that results in increased hepatic glucose output and subsequently hyperglycemia.2 In a study that compared the effect of vildagliptin and glimepiride on prandial glucagon » » » [Read more]